Track topics on Twitter Track topics that are important to you
ANN ARBOR, Mich., Feb. 24, 2017 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (TSX-V:ZOM) ("Zomedica" or the "Company"), a veterinary pharmaceutical and health care solutions company, today announced the grant of an aggregate of 535,000 options to acquire common shares of the Company to an officer and to an employee of the Company, each such option being exercisable at a price of C$1.50 per common share for a two-year term expiring on February 24, 2019. The stock options have all vested immediately upon the date of grant. The stock options, and any common shares issued upon exercise of the stock options, are subject to a four-month hold period expiring on June 25, 2017.
The Company further announces that it has entered into an agreement to settle an amount of US$50,000 (approximately C$65,420.00) via the issuance of an aggregate of 43,613 common shares of the Company at a price of C$1.50 per share. The foregoing Shares for Debt transaction is subject to approval by the TSX Venture Exchange. In addition, Zomedica also advises that its' previously announced non-brokered private placement offering of 6,657,520 common shares at a price of C$1.50 per common share is ongoing. The first tranche of this offering was completed on December 29, 2016, with an aggregate of 791,373 Common Shares having been issued for aggregate gross proceeds of C$1,187,059.50. All of the foregoing shares will, upon issuance, be subject to a statutory four-month hold period in accordance with applicable securities laws.
The securities offered have not been registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), or applicable state securities laws, and may not be offered or sold to persons in the United States absent registration or an exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.
With U.S. operations based in Ann Arbor, Michigan, Zomedica is a veterinary pharmaceutical and health care solutions company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. Zomedica is developing a diversified portfolio to include innovative drugs, drug-delivery technologies, diagnostics, and devices. With multiple clinical veterinarians in executive management, it is Zomedica’s mission to give veterinarians the opportunity to lower costs, increase productivity, and grow revenue while better serving the animals in their care. For more information, visit www.ZOMEDICA.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the release.
Except for statements of historical fact, this news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.
Forward-looking information is based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: uncertainty as to whether our strategies and business plans will yield the expected benefits; availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to future clinical trials, regulatory approvals, safety and efficacy of our products, the use of our product, intellectual property protection and the other risk factors disclosed under our profile on SEDAR at www.sedar.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.
The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.
Investor Relations Contact Shameze Rampertab, CPA, CA email@example.com +1 647.283.3630 Barry Mire, Renmark Financial Communications Inc. firstname.lastname@example.org +1 416.644.2020 or +1 514.939.3989 Media Contact Andrea Eberle email@example.com +1 734.369.2555NEXT ARTICLE
Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...